A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma
George Shenouda(McGill University Health Centre), Bassam Abdulkarim(University of Alberta), Luís Souhami(McGill University Health Centre), Valérie Panet-Raymond(McGill University Health Centre), Scott Owen(McGill University Health Centre), Andrea Corredor(McGill University), Marie‐Christine Guiot(McGill University), Kevin Petrecca(McGill University Health Centre)
International Journal of Radiation Oncology*Biology*Physics
November 15, 2016
Cited by 58
Related Papers
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05
|International Journal of Radiation Oncology*Biology*Physics|2000|1.6k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k